Browse studies

Find your next paid study

27,292 recruiting studies available now

Preventing Financial Adversity Among Early-Stage Cancer Patients Through Unrestricted Cash (PAYMENT) Pilot Study

This clinical trial studies whether an unrestricted cash payment program can be used to improve financial and clinical outcomes in early-stage cancer patients …

Malignant Solid Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06771739

Phase 3

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metas…

Medulloblastoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Nationwide Children's HospitalNCT07291102

Phase 2

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjug…

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06311214

Phase 1

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced u…

Ovarian CancerPancreas CancerUrothelial Carcinoma+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nammi Therapeutics IncNCT06582017

Phase 2

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult p…

Primary Membranous Nephropathy

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AstraZenecaNCT07571746

Phase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Period and Long-term Extension to Assess the Efficacy and Safety of Rilzabrutinib in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb respo…

Autoimmune Haemolytic Anaemia

Estimated

~$50 – $2,250

Actual pay is set by the research site.

SanofiNCT07086976

Phase 1

Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a pe…

Recurrent Plasmablastic LymphomaRefractory Plasmablastic Lymphoma

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07332507

Phase 1

POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time…

Type 1 Diabetes (T1D)Type 1 Diabetes Mellitus

Estimated

~$150 – $4,200

Actual pay is set by the research site.

GentiBio, IncNCT06919354

Observational

Building Resilience in Skilled Nursing Care: Open Pilot for a Behavioral Health Intervention

The goal of this clinical trial is to test a behavioral health program (Interventions for Stressful Transitions in Later Life, InSTILL, for Individuals) for sk…

Nursing Home ResidentSkilled Nursing FacilityDepression+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts General HospitalNCT07655232

Phase 2

A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection

The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital…

Human Papilloma Virus (HPV)High-risk Human Papillomavirus Infection

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Daré Bioscience, Inc.NCT07601074

Fasting Hypoglycemia: Diagnosis and Treatment

Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia. Patients i…

HypoglycemiaInsulinoma

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001276

Phase 3

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (d…

Metastatic Castration-resistant Prostate Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

AmgenNCT07213674